BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Bevacizumab: trial readouts and FDA decisions

16 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 12 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd., AstraZeneca, AbbVie, Hoffmann-La Roche, Genelux Corporation, Mabscale, LLC, Delcath Systems Inc., Shenyang Sunshine Pharmaceutical Co., LTD.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3Hoffmann-La RocheNCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Canceractive not recruiting382
2026-12 est.P3Genelux Corporation GNLXNCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/RefractoryPlatinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primarrecruiting186
2026-12 est.P3Mabscale, LLCNCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerNon-Small Cell Lung Cancerrecruiting620
2026-12 est.P2AbbVie ABBVNCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable MetUnresectable Metastatic Colorectal Canceractive not recruiting280
2026-12 est.P2Delcath Systems Inc. DCTHNCT06607458 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or ApprRefractory Metastatic Colorectal Cancerrecruiting90
2026-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerOvarian Cancerrecruiting150
2026-12 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ducnot yet recruiting300
2026-12-01 est.P2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06683703 Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesNon-small Cell Lung Cancer Patients with Brain Metastasesnot yet recruiting118
2026-12-24 est.P2Nanjing Leads Biolabs Co.,LtdNCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Advanced Solid Tumourrecruiting250
2026-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting93
2026-12-31 est.P1/P2AskGene Pharma, Inc.NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.Advanced Solid Tumorsrecruiting594
2026-12-31 est.P3NaviFUS CorporationNCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) UGlioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Turecruiting32
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89
2027-01-13 est.P3AkesoNCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal CancerColorectal Adenocarcinomarecruiting560
2027-01-19 est.P1/P2Sanofi SNYNCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSolid Tumorrecruiting542
2027-02-10 est.P2AstraZeneca AZNNCT06271837 A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)active not recruiting127

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Regeneron Pharmaceuticals REGNNCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersAdvanced Solid Tumorsactive not recruiting548
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-10 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06618664 A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Advanced Hepatocellular Carcinomarecruiting590
2026-10 est.P1/P2Biotheus Inc.NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCHCC; Liver Cancernot yet recruiting140
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerAdvanced or Metastatic Non-small Cell Lung Cancerrecruiting248
2026-10 est.P1/P2Immunocore Ltd IMCRNCT04262466 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsSelect Advanced Solid Tumorsactive not recruiting410
2026-09-05 est.P1/P2Bristol-Myers Squibb BMYNCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting360
2026-09 est.P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06558227 Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown90
2026-09 est.P2/P3Bio-Thera SolutionsNCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical Cancerrecruiting526
2026-06-30P2AstraZeneca AZNNCT06040099 A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Hepatocellular Carcinoma (HCC)active not recruiting58
2026-06-30 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05444088 Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinomaunknown129

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.